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Granulosa cell tumors (GCTs) of the ovary account for 2 to 5 of ovarian malignancies. We present two patients with
malignant ovarian adult GCT. In one patient, a combination of bleomycin, etoposide, and cisplatin was effective
after initial surgery for malignant GCT. In the other, an aromatase inhibitor was effective for recurrent malignant
GCT. We also review the literature for further management of this tumor. Because GCT of the ovary is rare, it will be
necessary to elucidate the clinical phenotype and establish treatment protocols by accumulating and analyzing
more patients.
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Granulosa cell tumors (GCTs) of the ovary comprise 2 to
5% of malignant ovarian tumors [1,2], and 20 to 30%
show malignant clinical and histopathological characteris-
tics. The clinical outcome for tumors at stages I and II is
excellent, whereas those at stages III and IV remains poor
[3]. The 5-year survival rate for GCTs is approximately
80% overall, and some patients experience relapse 20 to
30 years after the initial surgery [4,5]. There are few
reports on the clinical phenotype of malignant progres-
sion [6], and no standard therapy has yet been established
[7]. We report our experience of two patients with malig-
nant GCT, and review the literature.
Case reports
Patient 1
A 26-year-old woman presented to her doctor in
December 2010 with abdominal pain and bloating. She
had never been pregnant, but had a history of surgery for
patent ductus arteriosus (at the age of 1 year) and also
had type 2 diabetes. A pelvic neoplasm was suspected,
and the patient was referred our department in January
2011 for detailed investigation and treatment.* Correspondence: yokoyama@cc.hirosaki-u.ac.jp
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reproduction in any medium, provided the orAbdominal ultrasonography showed a mass, with
hyperechogenicity. On magnetic resonance imaging
(MRI) scan, an irregular, solid mass, 130 mm in size, was
seen in the peritoneal cavity with associated pelvic asci-
tes. Computed tomography (CT) showed enlargement of
the left subclavian, para-aortic, and pelvic lymph nodes,
and metastasis was thus suspected. No abnormality was
seen with peripheral blood tests and biochemical tests,
but the level of a tumor marker, CA125, was raised (233
U/ml; normal range 0 to 35 U/ml).
A diagnosis of malignant ovarian tumor was made, and
surgery was performed. The laparoscopic findings indi-
cated that the mass was an irregular, solid tumor derived
from the left ovary. Because multiple distant metastases
were present, a left adnexectomy was performed.
The cut surface of the tumor was yellowish and friable
(Figure 1). On pathological examination, oval, atypical
cells were seen, proliferating in a cord-like or alveolar
configuration, and Call-Exner bodies were visible in
some areas. Immunohistochemical staining gave positive
results for alpha-inhibin. Under microscopic examin-
ation, 10 or more mitoses were present per high power
field (Figure 2).
Based on these results, a malignant GCT of the ovary
(Fédération Internationale de Gynécologie et d'Obstétrique
(FIGO) stage IV) was diagnosed. After surgery, the patientLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Patient 1: macroscopic appearance of the tumor. The cut surface of the tumor was yellowish and friable.
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20 mg/m2 on days 2, 9, and 16; etoposide 100 mg/m2 on
days 1 to 3; cisplatin 15 mg/m2 on days 1 to 5) every
3 weeks.
A CT scan performed after the completion of two cycles
showed a reduction in the size of lesions in lymph nodes
at all sites. However, pyrexia and respiratory discomfort
occurred, and worsened after the completion of three
cycles. The patient was treated for a provisional diagnosis
of drug-induced interstitial pneumonia, but her respira-
tory condition failed to improve, and she died as a result
of respiratory failure caused by interstitial pneumonia.
Patient 2
A 59-year-old woman was diagnosed with an ovarian
tumor in December 1998, for which she underwentFigure 2 Patient 1: histological appearance of the tumor. Atypical cells
Call-Exner bodies were seen in some areas. Ten or more mitoses were preslaparotomy. She had been pregnant four times and had
three children; she had no other medical history of note.
An intraoperative rapid pathological diagnosis of GCT
was made, and a simple total hysterectomy, bilateral
adnexectomy, omentectomy, pelvic lymphadenectomy,
and para-aortic lymphadenectomy were performed. The
tumor was an irregular mass derived from the left ovary.
Although the cut surface was pale-yellow and mostly
solid, cystic areas containing mucus were visible in some
parts (Figure 3). The tumor was assessed as FIGO stage
Ic. Adjuvant therapy was not given.
An abdominal CT performed in February 2004 showed
an intraperitoneal mass, indicating tumor recurrence. The
patient was given 10 cycles of chemotherapy (IEP: ifosfa-
mide 800 mg/m2 on days 1 to 3; epirubicin 50 mg/m2 on
day 1; ciclosporin 15 mg/m2 on days 1 to 5), with onewere seen proliferating in a cord-like or alveolar configuration, and
ent per high power field.
Figure 3 Patient 2: macroscopic appearance of the initial tumor. The cut surface was pale-yellow and mostly solid, with cystic areas
containing mucus visible in some parts.
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size of the lesion. However, re-expansion of the deposits
occurred, and total resection of the intraperitoneal recur-
rences was attempted in October 2006 (Figure 4). All
recurrences presented as multiple intraperitoneal masses,
ranging in size from 50 to 100 mm. The cut surface of
the tumors was pale yellow and solid, and cystic areas
containing mucus were seen in some areas (Figure. 4),
indicating macroscopic findings similar to those at the
time of initial surgery. Based on the post-operative
pathological examination, a malignant GCT was diag-
nosed, and the patient was given six cycles of post-
operative chemotherapy (TC: paclitaxel 180 mg/m2 on
day 1; carboplatin (area under the curve 5) on day 1)
every 3 weeks.
A CT scan in April 2009 indicated an intraperitoneal
mass, and a second resection of recurrent, intraperito-
neal masses was performed in May 2009. Total resection
was also attempted on this occasion. After surgery, the
patient was treated with an oral aromatase inhibitor
(anastrozole) 1 mg/day, but a CT scan in September
2010 showed recurrent intraperitoneal masses. Because
enlargement was also seen, a third, complete resection
was attempted in May 2011. Pathological examination
showed atypical cells proliferating in a mixed solid and
cystic manner in all specimens in the recurrencesobtained in 1998, 2006, 2009, and 2011, and Call-Exner
bodies, coffee bean-like cells, and mitoses were also vis-
ible (Figure 5). Immunohistochemistry gave a positive
result for alpha-inhibin.
Based on the above results, a malignant GCT was
diagnosed. Oral administration of anastrozole 1 mg/day
has continued with the patient followed up as an out-
patient, and this has resulting in disease-free survival to
the most recent follow-up (April 2012).
Discussion
Ovarian GCT is classified as a sex cord-stromal tumor
and is treated as a borderline malignant tumor. These
tumors show the clinical and pathological features of
malignancy at a rate of 20 to 30%, and comprise 2 to 5%
of ovarian malignant tumors [1,2]. Prognostically, the 5-
year survival rate of patients with stage I or II disease is
thought to be 95%, and that of patients with stage III or
IV disease is 59% [8]. However, some patients experience
relapse 20 to 30 years after the initial surgery [4,5], and
there have been a few reports published on the clinical
phenotype of those with rapid progression [6]. Jozwicki
et al. reported a patient with a very aggressive ovarian
GCT, composed of granulosa, sarcomatoid, and fibrothe-
comatous tissues [6]. The tumor recurred rapidly, and
the patient died 16 months later [6].
Figure 4 Patient 2: macroscopic appearance of the recurrent tumor. As with the initial tumor, the cut surface was pale-yellow and solid,
with cystic areas containing mucus seen in some parts.
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cells with a coffee bean-like longitudinal nuclear groove
and a micro-follicular structure termed the ‘Call-Exner
body’. In patients with malignancy, a large number of
mitoses and dyskaryoses are also seen. According to one
report, the number of mitoses is a pathological prognos-
tic factor [9]. Alpha Inhibin-alpha is a sensitive immuno-
histochemical marker of GCT of the ovary, and is of
value in the differential diagnosis of ovarian neoplasia
[10] as shown in the two patients presented.
Because it is difficult to distinguish GCTs from epithe-
lial ovarian tumors pre-operatively, and because the ac-
curacy of intraoperative rapid pathological diagnosis is
not good, basic techniques used for the management of
ovarian cancer (bilateral adnexectomy plus+totalFigure 5 Patient 2: histological appearance of the recurrent tumor. Cahysterectomy+plus omentectomy) and staging laparot-
omy are recommended as the initial therapy [11]. Indica-
tions and protocols for adjuvant therapy have not yet
been established because GCTs are rare, and a large-
scale clinical study has not been conducted. In general,
chemotherapy is recommended for patients with residual
foci, a high risk of recurrence (tumor rupture, stage Ic
or greater, a poorly differentiated tumor, or a tumor
diameter of >100 to 150 mm); or actual recurrence. PVB
(cisplatin + vinblastin + bleomycin) therapy [12] and BEP
(bleomycin + etoposide + cisplatin) therapy [13] are con-
sidered effective regimens, based on the results of clin-
ical studies that showed a relatively high response rate.
The target of both therapies is the progressive, recurrent
GCT, and the response rates to PVB and BEP therapiesll-Exner bodies, coffee bean-like cells, and mitoses were visible.
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though retrospective, a study of the combination therapy
of taxane-based drugs and platinum-based drugs in
patients with recurrences showed a response rate of 54%
[14]. Drugs with an anti-estrogenic effect, such as
gonadotropin-releasing hormone agonists and aromatase
inhibitors, have recently been suggested to be effective
[15-17]. Aromatase inhibitors exhibit an anti-estrogen
effect by binding to aromatase, an enzy\me required for
the conversion of androgen to estrogen, and inhibiting
its activity. Although aromatase inhibitors are used clin-
ically to treat post-menopausal women with estrogen
receptor-positive breast cancer [18], there are some
reports of patients in whom an aromatase inhibitor
was effective against GCTs with repeated recurrences
[15-17], as for patient 2.
Patient 1 had a reduction in the size of lesions in
lymph nodes after BEP therapy, confirming the efficacy
of the treatment. However, because serious interstitial
pneumonia also occurred in this patient, as has been
reported for other cases in which bleomycin was impli-
cated in treatment-related death, the use of this treat-
ment needs to be reconsidered. By contrast, even though
the intraperitoneal tumor recurred in patient 2 after the
start of aromatase inhibitor administration, the tumors
were small, suggesting that the aromatase inhibitor slo-
wed tumor growth, and that this drug is effective against
recurrent tumors.
Conclusions
The results for our two patients suggest that BEP ther-
apy is effective after initial surgery and that an aromatase
inhibitor is effective for recurrent tumors. However, be-
cause GCTs are rare, it will be necessary to elucidate the
clinical phenotype and establish treatment protocols by
accumulating and analyzing more patients.
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